Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEAN-RAPHAEL R SCHNEIDER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1487691127
CMS profile
249229
Location
CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$39,887.72

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEAN-RAPHAEL R SCHNEIDER

NPI 1487691127 · CMS profile ID 249229

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CLEARWATER, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487691127?year=2025&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487691127?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487691127?year=2025&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JEAN-RAPHAEL R SCHNEIDER, NPI 1487691127, CMS profile ID 249229, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–237 of 237 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1487691127?year=2025&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $39,887.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–237 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $31.6603/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251845177 CMS
PFIZER INC. $24.3003/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231530801 CMS
Cycle Pharmaceuticals Inc $31.7103/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248902742 CMS
AstraZeneca Pharmaceuticals LP $21.5203/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206966019 CMS
Vanda Pharmaceuticals Inc. $26.7503/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233001532 CMS
UCB, Inc. $40.3803/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405180 CMS
Tanabe Pharma America, Inc. $33.7903/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243917530 CMS
Alnylam Pharmaceuticals Inc. $38.2503/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212768733 CMS
ABBVIE INC. $22.4603/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115304 CMS
Eisai Inc. $23.4403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244485195 CMS
PFIZER INC. $20.3503/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231375437 CMS
ABBVIE INC. $20.2203/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115297 CMS
Alexion Pharmaceuticals, Inc. $45.9302/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202958770 CMS
PFIZER INC. $15.3002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229206957 CMS
ARGENX US, INC. $30.4402/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240421878 CMS
GENZYME CORPORATION $12.6502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233394826 CMS
SCILEX PHARMACEUTICALS INC. $22.8702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242589919 CMS
Neurocrine BioSciences, Inc. $16.8002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243037883 CMS
UCB, Inc. $23.5102/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405178 CMS
Grifols USA, LLC $22.3402/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249557928 CMS
Biogen, Inc. $28.1302/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208460101 CMS
ABBVIE INC. $21.4002/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115285 CMS
ABBVIE INC. $23.2102/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115291 CMS
UCB, Inc. $37.4602/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405176 CMS
Lundbeck LLC $32.5302/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251845175 CMS
Celgene Corporation $16.3602/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184468828 CMS
Alnylam Pharmaceuticals Inc. $38.2501/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212768715 CMS
Grifols USA, LLC $20.8901/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249557923 CMS
UCB, Inc. $31.9901/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224405174 CMS
TG Therapeutics, Inc. $29.8701/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226237950 CMS
ABBVIE INC. $20.4201/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115279 CMS
ABBVIE INC. $24.5101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204115274 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.0901/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223913096 CMS
Tanabe Pharma America, Inc. $34.9601/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243917506 CMS
Eisai Inc. $14.1401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244485193 CMS
PFIZER INC. $26.0301/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231133540 CMS
Vanda Pharmaceuticals Inc. $20.1601/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233001530 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $80,532.16 244
PY2020 $17,258.79 201
PY2021 $15,732.24 222
PY2022 $24,018.05 228
PY2023 $16,862.02 217
PY2024 $24,262.82 227
PY2025 $39,887.72 237

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $421,658.88 45
PY2024 Principal investigator $573,984.19 31
PY2023 Principal investigator $425,295.33 31
PY2022 Principal investigator $602,220.97 35
PY2021 Principal investigator $460,918.62 27
PY2020 Recipient $129.92 1
PY2020 Principal investigator $374,459.26 18
PY2019 Recipient $2,491.26 10
PY2019 Principal investigator $101,900.00 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Hoffmann-La Roche Limited $1,062.00 12/16/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626518
Principal investigator 1 Hoffmann-La Roche Limited $52.50 12/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626514
Principal investigator 1 Hoffmann-La Roche Limited $250.00 12/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211626522
Principal investigator 1 TG Therapeutics, Inc. $25,000.00 11/30/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200807
Principal investigator 1 Genentech, Inc. $200.00 11/18/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626561
Principal investigator 1 Genentech, Inc. $5,418.00 11/06/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626565
Principal investigator 1 TG Therapeutics, Inc. $125.00 11/04/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200812
Principal investigator 1 TG Therapeutics, Inc. $12,025.00 11/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200805
Principal investigator 1 Genentech, Inc. $100.00 10/08/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626549
Principal investigator 1 TG Therapeutics, Inc. $150.00 10/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200809
Principal investigator 1 TG Therapeutics, Inc. $10,100.00 09/30/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200789
Principal investigator 1 Genentech, Inc. $11,710.00 09/19/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626557
Principal investigator 1 Genentech, Inc. $10,233.00 09/18/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626554
Principal investigator 1 GENZYME CORPORATION $2,452.50 09/15/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117294
Principal investigator 1 Alexion Pharmaceuticals, Inc. $500.00 09/04/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185547079
Principal investigator 1 TG Therapeutics, Inc. $3,850.00 08/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200787
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,630.88 08/19/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305769
Principal investigator 1 TG Therapeutics, Inc. $75.00 08/04/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200791
Principal investigator 1 Genentech, Inc. $292.00 08/01/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626544
Principal investigator 1 TG Therapeutics, Inc. $4,025.00 07/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200785
Principal investigator 1 Genentech, Inc. $192.00 07/29/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626540
Principal investigator 1 GENZYME CORPORATION $316.00 07/28/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226117283
Principal investigator 1 GENZYME CORPORATION $11,522.90 07/28/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117289
Principal investigator 1 GENZYME CORPORATION $2,600.00 07/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117278
Principal investigator 1 Genentech, Inc. $600.00 06/10/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626528
Principal investigator 1 TG Therapeutics, Inc. $8,175.00 06/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200719
Principal investigator 1 TG Therapeutics, Inc. $200.00 05/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200721
Principal investigator 1 GENZYME CORPORATION $3,780.00 05/19/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226117266
Principal investigator 1 GENZYME CORPORATION $4,292.10 05/19/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117271
Principal investigator 1 TG Therapeutics, Inc. $3,525.00 05/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200725
Principal investigator 1 Genentech, Inc. $19,005.00 04/15/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626537
Principal investigator 1 GENZYME CORPORATION $1,000.00 04/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117253
Principal investigator 1 GENZYME CORPORATION $1,762.50 04/02/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226117258
Principal investigator 1 Genentech, Inc. $542.00 04/02/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626535
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 03/31/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200727
Principal investigator 1 TG Therapeutics, Inc. $900.00 03/20/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200723
Principal investigator 1 TG Therapeutics, Inc. $3,500.00 02/28/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200729
Principal investigator 1 Hoffmann-La Roche Limited $52.00 02/06/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211626573
Principal investigator 1 Genentech, Inc. $100.00 02/05/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211626532
Principal investigator 1 TG Therapeutics, Inc. $10,600.00 02/01/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200731
Principal investigator 1 Novartis Pharmaceuticals Corporation $21,464.25 01/28/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190310038
Principal investigator 1 GENZYME CORPORATION $10,450.00 01/21/2025 Non-covered Recipient Entity
Ms And Neuromuscular Center Of Excellence
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226117246
Principal investigator 1 TG Therapeutics, Inc. $15,175.00 01/06/2025 Non-covered Recipient Entity
MS & Neuromuscular Center of Excellence LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200733
Principal investigator 1 Hoffmann-La Roche Limited $250.50 01/02/2025 Non-covered Recipient Entity
MS NEUROMUSCULAR CENTER OF EXCELLENCE LLC
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211626568
Principal investigator 1 Novartis Pharmaceuticals Corporation $210,103.75 01/01/2025 Non-covered Recipient Entity
MS AND NEUROMUSCULAR CENTER OF EXCELLENCE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190305771